title: Basophil responsiveness and clinical picture of acetylsalicylic acid intolerance.
abstract: BACKGROUND
  Exposure to acetylsalicylic acid (ASA) may exacerbate respiratory or skin diseases or induce anaphylactoid reactions in apparently healthy individuals. We wanted to evaluate specific responsiveness of basophils to ASA in correlation with the clinical picture.
  
  
  METHODS
  We performed a prospective single-blind study of 59 subjects involved in clinical evaluation and/or ASA provocation testing. Whole blood basophils were stained with anti-CD63/CD123/HLA-DR mAbs after stimulation with 0.25 or 1 mg/ml ASA.
  
  
  RESULTS
  We found that 40 subjects were ASA tolerant and 19 were ASA intolerant. Both groups had comparable manifestations of asthma and/or rhinitis (13 in the tolerant and 9 in the intolerant group). Intolerant subjects showed significantly higher basophil responsiveness to ASA in comparison to tolerant subjects, which was concentration-dependent in both groups. The ratio between responses at 1 mg/ml of ASA and at baseline (activation index) was analyzed according to the clinical picture. We demonstrate that the activation index was higher only in the intolerant subjects with anaphylactoid reactions, but not in a subgroup of subjects with asthma/rhinitis. The ROC calculations show that the optimal threshold activation index was more than 2.18. The sensitivity was 80% and the specificity was 83% in the subgroup with anaphylactoid reactions. In the asthma/rhinitis subgroup, the sensitivity was 78% and the specificity was 50%.
  
  
  CONCLUSIONS
  Our study demonstrates that there is a significantly higher in vitro basophil response to ASA in intolerant as compared to tolerant subjects. ROC analyses suggest that this measurement might only have a diagnostic value in subjects without asthma and/or rhinitis.
authors.affiliation: University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia. peter.korosec@klinika-golnik.si
authors.forename: Peter
authors.initials: P
authors.lastname: Korosec
authors.forename: Nusa
authors.initials: N
authors.lastname: Mavsar
authors.forename: Nissera
authors.initials: N
authors.lastname: Bajrovic
authors.forename: Mira
authors.initials: M
authors.lastname: Silar
authors.forename: Ales
authors.initials: A
authors.lastname: Mrhar
authors.forename: Mitja
authors.initials: M
authors.lastname: Kosnik
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000276:immunology; D001241:Aspirin / Q000009:adverse effects; D055963:Asthma, Aspirin-Induced / Q000175:diagnosis* / Q000276:immunology; D015549:Basophil Degranulation Test; D001491:Basophils / Q000187:drug effects* / Q000276:immunology; D005260:Female; D006684:HLA-DR Antigens / Q000276:immunology; D006801:Humans; D053650:Interleukin-3 Receptor alpha Subunit / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010980:Platelet Membrane Glycoproteins / Q000276:immunology; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D060149:Tetraspanin 30
chemical_list: D015703:Antigens, CD; C554586:CD63 protein, human; D006684:HLA-DR Antigens; C115022:IL3RA protein, human; D053650:Interleukin-3 Receptor alpha Subunit; D010980:Platelet Membrane Glycoproteins; D060149:Tetraspanin 30; D001241:Aspirin